Article
Oncology
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: A retrospective evaluation of mCRC patients receiving anti-EGFR monoclonal antibody treatment identified liver metastasis as an independent risk factor for skin toxicities and prophylactic administration of antibiotics as a preventive factor. The study suggests that preemptive antibiotic use can decrease the risk of skin toxicities during anti-EGFR treatment.
SUPPORTIVE CARE IN CANCER
(2023)
Review
Biochemistry & Molecular Biology
Chao Wang, Yujing Zhang, Tingting Zhang, Jiazhen Xu, Saisai Yan, Bing Liang, Dongming Xing
Summary: Overexpression of EGFR has been linked to various cancers, and drug resistance caused by EGFR mutations is a significant challenge. EGFR dual-target inhibitors show promise in overcoming drug resistance and have higher efficacy compared to single-target inhibitors.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Oncology
Wen Zhang, Xiaohong Han, Lin Yang, Yuanyuan Song, Liangzhi Xie, Wenlin Gai, Yan Wang, Yuankai Shi
Summary: SCT200 demonstrated favorable safety, pharmacokinetic profile, and preliminary efficacy in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer, with low toxicity.
Review
Oncology
Swathi R. Shetty, Ragini Yeeravalli, Tanya Bera, Amitava Das
Summary: EGFR, a crucial transmembrane protein with tyrosine kinase activity, is overexpressed in various cancers triggering tumor progression and drug resistance; Inhibition of EGFR modulates chemosensitivity in breast cancer stem cells, serving as a potential drug target for breast cancer mitigation; Tyrosine kinase inhibitors and monoclonal antibodies targeting EGFR have been developed and approved for clinical use against breast cancer.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, Nobuyuki Yamamoto
Summary: This study aimed to determine the incidence and clinical course of histologic transformation (HT) in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The study found that approximately 3% of EGFR-mutated patients developed HT after acquiring resistance to EGFR-tyrosine kinase inhibitors (TKIs). There was no significant difference in survival between patients with transformation to high-grade neuroendocrine carcinoma and those with transformation to another subtype of non-small cell lung cancer. Cytotoxic agents were likely to be effective in patients with HT, while the effectiveness of immune checkpoint inhibitors was limited.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Avinash Khadela, Yesha Shah, Priya Mistry, Mustakim Mansuri, Dipen Sureja, Kunjan Bodiwala
Summary: A combination of monoclonal antibodies along with standard of care has the potential to improve head and neck cancer patients' conditions and quality of life. Immunotherapy is a promising approach and exploring new targets and drugs is crucial.
Article
Oncology
Jianming Xu, Jieer Ying, Rongrui Liu, Jun Wu, Feng Ye, Nong Xu, Yanqiao Zhang, Rusen Zhao, Xiaojun Xiang, Jianhong Wang, Xiaoyan Lin, Huiting Xu, Shegan Gao, Suxia Luo, Baohong Guo, Xionghui Li, Yangzhi Su, Qian Wang
Summary: This study reports the safety and efficacy results of a phase 2 trial using a novel human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody KN026 in patients with advanced HER2-expressing gastric or gastroesophageal junction cancer. The results showed that KN026 has a favorable safety profile and promising anti-tumor activity.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Cell Biology
Yuanzhou Zhang, Shunshun Liang, Bowen Xiao, Jingying Hu, Yechun Pang, Yuling Liu, Juan Yang, Junpin Ao, Lin Wei, Xiaoying Luo
Summary: This study shows that ErbB3/EGFR receptor tyrosine kinase activity is increased in colorectal cancer cells, and miR-323a-3p can directly target both ErbB3 and EGFR, promoting apoptosis in CRC cells. Furthermore, miR-323a-3p acts as a multi-ErbBs inhibitor, enhancing sensitivity to gefitinib and preventing acquired resistance.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Jordi Codony-Servat, Silvia Garcia-Roman, Miguel Angel Molina-Vila, Jordi Bertran-Alamillo, Santiago Viteri, Erik d'Hondt, Rafael Rosell
Summary: The study indicates that anti-EGF antibodies generated by vaccination can enhance the antitumor activity of TKIs in ALK and RET-positive NSCLC cell lines, improving the efficacy of kinase inhibitors and delaying the emergence of resistant clones. This suggests that combining EGF vaccine with ALK and RET TKIs in clinical trials may be beneficial for advanced NSCLC patients with EML4-ALK and CCDC6-RET rearrangements.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Jing Zhao, Siying Li, Xuelei Pang, Yuping Shan
Summary: The therapeutic efficacy of nano-drugs targeting EGFR was evaluated in terms of cell entry efficiency and induced cell mechanical properties at the single particle/cell level in real time.
CHEMICAL COMMUNICATIONS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jasper Vonk, Jaron G. de Wit, Floris J. Voskuil, Yang Hang Tang, Wouter T. R. Hooghiemstra, Matthijs D. Linssen, Evert van den Broek, Jan J. Doff, Sebastiaan A. H. J. de Visscher, Kees-Pieter Schepman, Bert van der Vegt, Gooitzen M. van Dam, Max J. H. Witjes
Summary: This study investigated the use of fluorescence imaging to detect lymph node metastases in oral cancer patients. The results showed that fluorescence molecular imaging could accurately detect tumor-positive lymph nodes, reducing the need for microscopic assessment and identifying additional metastases missed by standard histopathologic analysis.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Oncology
Ryuhei Okada, Takuya Kato, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Daiki Fujimura, Shuhei Okuyama, Hideyuki Furumoto, Hiroshi Fukushima, Peter L. Choyke, Hisataka Kobayashi
Summary: This study compared the effects of Panitumumab and Cetuximab in APCs for NIR-PIT and the impact of different light exposure regimens on tumor growth in an immunocompetent mouse model. The results showed that APCs with longer half-life and double light exposure had superior outcomes in cancer cell-targeted NIR-PIT.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Lijuan Zhang, Meng Tian, Jiamao Lin, Jianbo Zhang, Haiyong Wang, Zhenxiang Li
Summary: The interaction between ER beta 1 and ER beta 5 in lung adenocarcinoma affects non-genomic signaling and resistance to EGFR TKIs. Cytoplasmic ER beta 1 may contribute to EGFR TKI resistance, and PC9/ER beta 1/5 cells show higher resistance to gefitinib.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Mengkai Yang, Tao Zhang, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai, Wei Sun
Summary: The study revealed that MYLK4 promotes the growth and metastasis of osteosarcoma by activating the EGFR signaling pathway. Additionally, the combination of MYLK4 and EGFR inhibitors showed synergistic effects on the growth and metastasis of OS in vitro and in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Biology
Yongjian Huang, Jana Ognjenovic, Deepti Karandur, Kate Miller, Alan Merk, Sriram Subramaniam, John Kuriyan
Summary: Research has shown that the EGFR receptor can adopt different conformations of the extracellular module when binding to different ligands, with implications for intracellular signaling pathways.
